Pharmaceuticals

Alcon, a division of Novartis, announced that it has acquired PowerVision, Inc., a privately-held, US-based medical device development company focused on creating fluid-based intraocular lens implants. The acquisition furthers Alcon’s commitment to bring...

Novartis announced an offer to acquire CellforCure from LFB. CellforCure, a French company, is one of the first and largest contract development and manufacturing organizations (CDMO) producing cell and gene therapies in Europe....

Novartis announced that Susanne Schaffert, Ph.D., currently President, Advanced Accelerator Applications (AAA), a Novartis company, has been appointed CEO Novartis Oncology. She will report to Vas Narasimhan, CEO, Novartis, and will join the...

The European Commission has granted marketing authorization for Dengvaxia®, Sanofi‘s dengue vaccine. The marketing authorization follows the October 18, 2018, recommendation by the European Medicines Agency’s Committee for Medicinal Products for Human Use...

The inauguration and ribbon cutting ceremony of Praava Health’s model pharmacy took place at on Thursday, December 13, 2018, in Banani, Dhaka. The ceremony was led by Ms. Sylvana Q. Sinha, Founder, Managing...

Swiss group Roche Holding AG said on Wednesday its Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the...

The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc’s drug to treat a form of blood cancer in newly diagnosed patients as a combination therapy. Pfizer plans to launch the drug,...

Alcon, the global leader in eye care and a division of Novartis, announced plans to develop the SMART Suite by Alcon, an innovative, digital platform that is designed to streamline, simplify and improve...

France’s Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma. Dupixent, co-developed with...

Johnson & Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial. Two doses of Stelara, already approved for psoriasis,...